This is a working overview of Reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
== External links == AGSD. - Association for Glycogen Storage Disease. A US-based non-profit, parent and patient oriented support group dedicated to promoting the best interest of all the different types of glycogen storage disease. AGSD-UK - Association for Glycogen Storage Disease (UK). A UK-based charity which helps individuals and families affected by Glycogen Storage Disease by putting people in contact, providing information and support, publishing a magazine and holding conferences, workshops, courses and family events. IamGSD - International Association for Muscle Glycogen Storage Disease. A non-profit, patient-led international group encouraging efforts by research and medical professionals, national support groups and individual patients worldwide. IPA - International Pompe Association. (Pompe Disease is also known as GSD-II). A non-profit, federation of Pompe disease patient's groups world-wide. It seeks to coordinate activities and share experience and knowledge between different groups. EUROMAC - EUROMAC is a European registry of patients affected by McArdle Disease and other rare neuromuscular glycogenoses. CoRDS - Coordination of Rare Diseases at Sanford (CoRDS) is a centralized international patient registry for all rare diseases. They work with patient advocacy groups, including IamGSD, individuals and researchers. CORD - Canadian Organization for Rare Disorders (CORD) is a Canadian national network for organizations representing all those with rare disorders.
222Rn, 3.82 days, alpha decaying to... 218Po, 3.10 minutes, alpha decaying to... 214Pb, 26.8 minutes, beta decaying to... 214Bi, 19.9 minutes, beta decaying to... 214Po, 0.1643 ms, alpha decaying to... 210Pb, which has a much longer half-life of 22.3 years, beta decaying to... 210Bi, 5.013 days, beta decaying to... 210Po, 138.376 days, alpha decaying to... 206Pb, stable The radon equilibrium factor is the ratio between the activity of all short-period radon progenies (which are responsible for most of radon's biological effects), and the activity that would be at equilibrium with the radon parent. If a closed volume is constantly supplied with radon, the concentration of short-lived isotopes will increase until an equilibrium is reached where the overall decay rate of the decay products equals that of the radon itself. The equilibrium factor is 1 when both activities are equal, meaning that the decay products have stayed close to the radon parent long enough for the equilibrium to be reached, within a couple of hours. Under these conditions, each additional pCi/L of radon will increase exposure by 0.01 working level (WL, a measure of radioactivity commonly used in mining). These conditions are not always met; in many homes, the equilibrium factor is typically 40%; that is, there will be 0.004 WL of daughters for each pCi/L of radon in the air.
=== Pharmaceuticals === Anticancer drugs that exert their pharmacological effect by interfering with menin's interactions include the approved drug revumenib and the experimental drugs bleximenib, enzomenib, icovamenib, and ziftomenib.
(2026) determine the age of the carbon black-based figures in the rock art from the Font-de-Gaume cave (France) on the basis of chemical imaging and radiocarbon dating. Parfitt et al. (2026) identify an Upper Paleolithic pendant made out of a polished seal tooth from the Kents Cavern (United Kingdom), which was an inland site during the Magdalenian occupation. Allaby et al. (2026) reconstruct the environment of the Southern River system in southern Doggerland on the basis of sedimentological and sedimentary ancient DNA, and report evidence indicating that early colonization of Doggerland was facilitated by presence of northern refugia during the early Mesolithic. Evidence indicating that early Paleo-Indians from eastern Beringia, North American Clovis complex and South American Fishtail Projectile Point complex were dietary specialists feeding on Pleistocene megafauna is presented by Potter et al. (2026). Eren et al. (2026) argue that Pleistocene sites in North America with proboscidean remains associated with Clovis points representing hunting and scavenging events cannot be reliably distinguished on the basis of available evidence, and argue that Clovis foragers likely practiced both hunting and scavenging of large Pleistocene mammals. Evidence from the study of assemblages of Pleistocene perishable objects from the Cougar Mountain Cave and Paisley Caves (Oregon, United States), indicative of complexity and sophistication of perishable technologies in the North American Great Basin during the Late Pleistocene, is presented by Rosencrance et al. (2026).
Sources: en.wikipedia.org
depends on temperature in a non-trivial way, and simple kinetic arguments as used here are inadequate. More fundamentally, the notion of a mean free path becomes imprecise for particles that interact over a finite range, which limits the usefulness of the concept for describing real-world gases.
=== Chemical synthesis === Synthetic taurine is obtained by the ammonolysis of isethionic acid (2-hydroxyethanesulfonic acid), which in turn is obtained from the reaction of ethylene oxide with aqueous sodium bisulfite. A direct approach involves the reaction of aziridine with sulfurous acid. In 1993, about 5000–6000 tonnes of taurine were produced for commercial purposes: 50% for pet food and 50% in pharmaceutical applications. In the laboratory, taurine can be produced by alkylation of ammonia with bromoethanesulfonate salts. Taurine can be synthesized in the laboratory from aziridines through a ring-opening reaction. The synthesis of taurine in the lab has been patented.
Within a three months period in 1980, at least ten Libyan dissidents were murdered in Europe, including ex-diplomats, ex-army officers, businessmen, journalists, and student activists in disparate locations such as London, Greece and Austria. At least eleven more were assassinated in 1981. In 1984, Gaddafi was tricked by Egyptian President Hosni Mubarak into announcing the assassination of former Libyan Prime Minister Abdul Hamid al-Bakkoush in Cairo; Bakkhoush not only turned up alive but held a press conference with Egypt's Interior Minister. In 1979, Gaddafi created the Islamic Legion, through which several thousand Africans were military trained. Libya had sought to improve US relations under President Jimmy Carter, for instance by courting his brother, businessman Billy Carter, and paying for the services of former CIA officers, but in 1979 the US placed Libya on its list of "State Sponsors of Terrorism". Relations were further damaged when a demonstration torched the US embassy in solidarity with the perpetrators of the Iran hostage crisis. Libyan fighters began intercepting US fighter jets flying over the Mediterranean, signalling the collapse of relations between the countries. Italian media have alleged that the Itavia Flight 870 was shot down during a dogfight involving Libyan, United States, French and Italian Air Force fighters in an assassination attempt by NATO members on a Libyan politician, perhaps even Gaddafi, flying in the same airspace.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.